drugset / Trial / NCT00532337

Controlled Study of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis

NCT00532337 ↗

Phase 2 Completed 285 enrolled Ono Pharma USA Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of ONO-5334 in postmenopausal women with osteopenia or osteoporosis.

Timeline

Start
2007-10
Primary completion
2010-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule 70 mg —
Comparator ONO-5334 Unknown 50 mg —
Comparator ONO-5334 Unknown 100 mg —
Comparator ONO-5334 Unknown 300 mg —

Indications